Tumor‐infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer

Inflammatory breast cancer (IBC) is a specific type of breast tumor that generally has a poor prognosis, in spite of recent advances in treatment. In the present study, semiquantitative reverse transcriptase polymerase chain reaction examination of resected specimens showed that angiogenic factors, not lymphangiogenic factors, are overexpressed in IBC tumors, compared with non‐IBC tumors. Immunohistochemical analysis of the specimens revealed a significantly higher population of tumor‐infiltrating (TI) endothelial cells (ECs) or endothelial precursor cells (EPCs) in tumor‐associated stroma of IBC specimens than in non‐IBC specimens. In a previous study, we examined the phenotype of host cells in response to transplanted IBC cells, using an established human IBC xenograft model (WIBC‐9) (Shirakawa et al., Cancer Res 2001;61:445–51). The data obtained in that study are consistent with the findings of the present study. To explore the therapeutic potential of blocking vascular endothelial growth factor (VEGF) and angiopoietin (Ang) pathways in IBC, established vectors encoding soluble Flt‐1 (sFlt‐1) and soluble Tie2 (sTie2) were injected directly into WIBC‐9. Both vectors produced growth inhibition ratios of WIBC‐9 that were significantly higher than those of a non‐IBC xenograft (MC‐5). Also, both vectors suppressed WIBC‐9 lung metastases. The efficacy correlated with the number of TI ECs/EPCs, which was determined by fluorescence‐activated cell sorting. These ECs/EPCs incorporated acetylated lipoprotein and were integrated within a HUVEC monolayer in vitro culture on day 5. © 2002 Wiley‐Liss, Inc.

[1]  D. Hinton,et al.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. , 2001, Blood.

[2]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[3]  T. Iwanaga,et al.  Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. , 2001, Cancer research.

[4]  T. Noda,et al.  A Role for Hematopoietic Stem Cells in Promoting Angiogenesis , 2000, Cell.

[5]  T. Murohara,et al.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. , 2000, The Journal of clinical investigation.

[6]  Y. Kaneda,et al.  Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes , 2000, Gene Therapy.

[7]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[8]  A. Quyyumi,et al.  Endothelial progenitor cells as putative targets for angiostatin. , 1999, Cancer research.

[9]  G. Martiny-Baron,et al.  Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. , 1999, Cancer research.

[10]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[11]  Hiroshi Takahashi,et al.  Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon , 1999, Nature Medicine.

[12]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[13]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[14]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. F. Pizzi,et al.  Inflammatory breast carcinoma: a community hospital experience. , 1998, Journal of the American College of Surgeons.

[17]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[18]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[19]  F. Graham,et al.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[22]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.